二次超声与乳腺X线摄影在MRI检出乳腺病变评估与活检中的价值
研究纳入212例女性在多参数乳腺MRI上检出的241个可疑病变,比较二次超声与二次乳腺X线摄影对不同特征病变的检出率及活检引导方式的选择,结果显示二次超声对>10 mm恶性肿块样病变敏感度高,而对非肿块样病变检出率低于二次乳腺X线摄影。
要点
- 二次超声对肿块样病变检出率55.6%,高于乳腺X线摄影的16.7%(p<0.001)。
- 二次超声对>10 mm恶性肿块样病变敏感度88.5%(95%CI 69.9-97.6%)。
- 二次超声对恶性非肿块样病变检出率22.0%,低于二次乳腺X线摄影的38.0%(p<0.001)。
核心结论
- 二次超声是无钙化且>10 mm可疑肿块样病变进一步评估与活检的优良工具,而对可疑非肿块样病变的评估和活检引导价值有限,不及二次乳腺X线摄影。
研究设计与样本
- 2021年1月至2023年12月,212例女性在3 Tesla下行乳腺多参数增强MRI,共241个可疑病变(108个恶性,44.8%)接受二次超声和二次乳腺X线摄影评估,随后按最合适的方式对每个病变行影像引导活检;采用McNemar检验比较二次超声与乳腺X线摄影按大小分层的病变检出率。
诊断标准与关键数值
- 二次超声对肿块样病变检出率55.6%(95%CI 46.4-64.4%),二次乳腺X线摄影为16.7%(95%CI 10.6-24.3%),p<0.001。
- 二次超声对>10 mm恶性肿块样病变敏感度88.5%(95%CI 69.9-97.6%)。
- 二次超声对恶性非肿块样病变检出率22.0%(95%CI 11.5-36.0%),二次乳腺X线摄影为38.0%(95%CI 24.7-52.8%),p<0.001。
- 转诊至MRI引导活检的病变以≤10 mm为主(52.8%)。
- 超声引导、乳腺X线引导和MRI引导活检的恶性率分别为53.7%、55.2%和35.0%。
临床应用与阅片要点
- 对MRI检出的可疑肿块样病变,尤其>10 mm且无相关钙化者,可优先尝试二次超声定位并引导活检。
- 对可疑非肿块样病变,二次超声的检出与活检引导价值有限,二次乳腺X线摄影可能更有利于评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Suspicious lesions detected in multiparametric breast MRI can be further analyzed with second-look ultrasound (SLUS) and/or mammography. This study aims to assess the value of second-look imaging in selecting the appropriate biopsy method for different lesion characteristics.
MATERIALS AND METHODS: Between January 2021 and December 2023, 212 women underwent contrast-enhanced multiparametric breast MRI at 3 Tesla. A total of 241 suspicious lesions (108 malignancies, 44.8%) were further assessed with SLUS and second-look mammography. Subsequent image-guided biopsy of each lesion was performed using the most suitable modality. Size-dependent lesion detection rates in SLUS and mammography were compared by means of the McNemar test.
RESULTS: Lesions referred to MRI-guided biopsy were predominantly ≤ 10 mm in size (52.8%). SLUS allowed for higher detection rates than mammography in mass lesions (55.6% [95% confidence interval 46.4-64.4%] versus 16.7% [10.6-24.3%]; p < 0.001) with a particularly high sensitivity for malignant mass lesions > 10 mm (88.5% [69.9-97.6%]). In contrast, the detection rate for malignant non-mass lesions was lower in SLUS than in second-look mammography (22.0% [11.5-36.0%] versus 38.0% [24.7-52.8%]; p < 0.001). The malignancy rates in ultrasound-, mammography-, and MRI-guided biopsies were 53.7%, 55.2%, and 35.0%, respectively.
CONCLUSION: SLUS is an excellent tool for further assessment and biopsy of suspicious mass lesions > 10 mm without associated calcifications. In contrast, supplemental ultrasound is of limited value in the evaluation and biopsy guidance of suspicious non-mass lesions compared to second-look mammography.
引用
- Sauer ST, Geerling J, Christner SA, et al. The Value of Second-look Ultrasound and Mammography for Assessment and Biopsy of MRI-detected Breast Lesions. Acad Radiol. 2024. PMID: 39510956. doi:10.1016/j.acra.2024.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。